Telix Pharmaceuticals (TLX,TLX.AX) reported a fiscal 2025 loss before income tax of $5.3 million compared to profit of $38.0 million, prior year. The company noted that the loss before tax includes $26.7 million in non-cash finance costs associated with convertible bonds and increased asset amortization of $11.9 million following the RLS Radiopharmacies acquisition. Adjusted EBITDA declined to $39.5 million from $66.9 million, last year.
For the year ended December 31, 2025, revenue increased to $803.8 million from $516.6 million, previous year. Precision Medicine segment revenue was up 22% year-over-year, driven by continued increase in Illuccix volumes and successful launch of Gozellix in the U.S.
For fiscal 2026, Telix projects Group revenue in a range of $950 million to $970 million.
Shares of Telix Pharma on Australian Securities Exchange are trading at A$10.43, up 14.24%. For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.